Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan

INTRODUCTION: Since 2019, for the first time, a two-drug regimen with dolutegravir/lamivudine (DTG/3TC) has been recommended for HIV treatment as initial and subsequent therapy in the international guidelines. However, safety and efficacy data of DTG/3TC in Japanese people living with HIV (PLHIV) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tofukuji, Ayano, Hongo, Haruyuki, Nagao, Takako, Sebata, Akemi, Suzuki, Miwako, Maeno, Yuko, Kurosaki, Eiji, Fukuda, Akiko, Watanabe, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070210/
https://www.ncbi.nlm.nih.gov/pubmed/36840899
http://dx.doi.org/10.1007/s12325-023-02459-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070210/
https://www.ncbi.nlm.nih.gov/pubmed/36840899
http://dx.doi.org/10.1007/s12325-023-02459-4

Ejemplares similares